Therapeutic regulation of autophagy in hepatic metabolism

Katherine Byrnes1, Sophia Blessinger1, Niani Tiaye Bailey1

  • 1Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA.

Keywords:
AIM, Atf8 interacting motifATGL, adipose triglyceride lipaseATL3, Atlastin GTPase 3ATM, ATM serine/threonine kinaseAutophagyBA, bile acidBCL2L13, BCL2 like 13BNIP3, BCL2 interacting protein 3BNIP3L, BCL2 interacting protein 3 likeCAR, constitutive androstane receptorCCPG1, cell cycle progression 1CLN3, lysosomal/endosomal transmembrane proteinCMA, chaperonin mediated autophagyCREB, cAMP response element binding proteinCRY1, cryptochrome 1CYP27A1, sterol 27-hydroxylaseCYP7A1, cholesterol 7α-hydroxylaseCryptochrome 1DFCP1, double FYVE-containing protein 1FAM134B, family with sequence similarity 134, member BFFA, free fatty acidFOXO1, Forkhead box O1FUNDC1, FUN14 domain containing 1FXR, farnesoid X receptorFarnesoid X receptorGABARAPL1, GABA type A receptor associated protein like 1GIM, GABARAP-interacting motifLAAT-1, lysosomal amino acid transporter 1 homologueLALP70, lysosomal apyrase-like protein of 70 kDaLAMP1, lysosomal-associated membrane protein-1LAMP2, lysosomal-associated membrane protein-2LD, lipid dropletLIMP1, lysosomal integral membrane protein-1LIMP3, lysosomal integral membrane protein-3LIR, LC3 interacting regionLXRa, liver X receptor aLYAAT-1, lysosomal amino acid transporter 1Liver metabolismLysosomeMCOLN1, mucolipin 1MFSD1, major facilitator superfamily domain containing 1NAFLD, non-alcoholic fatty liver diseaseNBR1, BRCA1 gene 1 proteinNCoR1, nuclear receptor co-repressor 1NDP52, calcium-binding and coiled-coil domain-containing protein 2NPC-1, Niemann-Pick disease, type C1Nutrient regenerationOPTN, optineurinPEX5, peroxisomal biogenesis factor 5PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinasePINK1, phosphatase and tensin homolog (PTEN)-induced kinase 1PKA, protein kinase APKB, protein kinase BPLIN2, perilipin 2PLIN3, perilipin 3PP2A, protein phosphatase 2aPPARα, peroxisomal proliferator-activated receptor-alphaPQLC2, PQ-loop proteinPXR, pregnane X receptorQuality controlRETREG1, reticulophagy regulator 1ROS, reactive oxygen speciesRTN3, reticulon 3RTNL3, a long isoform of RTN3S1PR2, sphingosine-1-phosphate receptor 2S6K, P70-S6 kinaseS6RP, S6 ribosomal proteinSCARB2, scavenger receptor class B member 2SEC62, SEC62 homolog, preprotein translocation factorSIRT1, sirtuin 1SLC36A1, solute carrier family 36 member 1SLC38A7, solute carrier family 38 member 7SLC38A9, sodium-coupled neutral amino acid transporter 9SNAT7, sodium-coupled neutral amino acid transporter 7SPIN, spindlingSQSTM1, sequestosome 1STBD1, starch-binding domain-containing protein 1Signaling proteinsTBK1, serine/threonine-protein kinaseTEX264, testis expressed 264, ER-phagy receptorTFEB/TFE3, transcription factor EBTGR5, takeda G protein receptor 5TRAC-1, thyroid-hormone-and retinoic acid-receptor associated co-repressor 1TRPML1, transient receptor potential mucolipin 1ULK1, Unc-51 like autophagy activating kinase 1UPR, unfolded protein responseV-ATPase, vacuolar-ATPaseVDR, vitamin D3 receptorVLDL, very-low-density lipoproteinWIPI1, WD repeat domain phosphoinositide-interacting protein 1mTORC1, mammalian target of rapamycin complex 1

Related Concept Videos

Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.7K
Regulation of Metabolism01:19

Regulation of Metabolism

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
10.2K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
10
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
8.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
6
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
5